 Shares of Neos Therapeutics NASDAQ:NEOS rose 4.2 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 37.50 over the past year to 0.11, which beat the estimate of 0.13.Revenue of 13,133,000 declined by 16.05 year over year, which beat the estimate of 12,170,000.Guidance Neos Therapeutics hasnt issued any earnings guidance for the time being.Neos Therapeutics hasnt issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Aug 10, 2020View more earnings on NEOSTime: 08:30 AMET Webcast URL: Stock Performance 52-week high: 2.1552-week low: 0.60Price action over last quarter: down 10.70Company Profile Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder ADHD using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.See more from Benzinga Earnings Scheduled For August 10, 2020C 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 